Abstract Library

#4403 Ki-67 index cut-off values and survival prognostication in neuroendocrine neoplasms: Machine learning-based insights

Introduction: The current grading system for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is based on Ki-67 index and/or mitotic rate. By definition, high-grade NEN (neuroendocrine tumour grade 3 [NET G3] and neuroendocrine carcinoma [NEC]) have a Ki-67 >20%, while NET G1 have a Ki-67

Conference:

Presenting Author:

Authors: Melhorn P, Berchtold L, Mazal P, Raderer M, Kiesewetter B,

Keywords: neuroendocrine neoplasm, prognosis, ki-67 index,

#4393 Surufatinib plus trans arterial embolisation (TAE) vs. surufatinib monotherapy in neuroendocrine tumour with liver metastasis: Updated results from the prospective, randomised, controlled trial

Introduction: The liver is the main metastasis site for NETs. Surufatinib (SUR), an oral TKI, is standard therapy for advanced NETs. TAE is the primary local intervention for unresectable hepatic NETs.

Conference:

Presenting Author: Cao D

Authors: Cao D, Li X, You X, Li R, Xiang J,

Keywords: NET, Liver metastasis, Surufatinib, TAE,

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#4364 Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma

Introduction: Radiolabelled therapy with meta-iodobenzguanine (MIBG) and chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine can help manage patients with metastatic pheochromocytoma and paraganglioma (mPPGL). The phase II FIRSTMAPPP study supports the use of the tyrosine kinase inhibitor sunitinib in these malignancies, with median progression-free survival values of 8.9 versus 3.6 months and overall response rates of 31% versus 8% for sunitinib versus placebo. The median duration of sunitinib therapy was 11 months. Concurrent with this study, we launched a single-arm trial to examine the activity of a similar tyrosine kinase inhibitor, axitinib.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Fojo T, Edgerly M, Pacak K, Figg W,

Keywords: PPGL, pheochromocytoma, paraganglioma, axitinib, TKI, tyrosinase kinase inhibitors,

#4113 Establishment of a rat model of diarrhea induced by Surufatinib

Introduction: Surufatinib is a novel oral small-molecule TKI for the treatment of advanced neuroendocrine tumors. However, diarrhea is a common adverse event of surufatinib which can affects patients’ quality of life and clinical efficacy. Currently, there are no available animal models to study the cause and treatmen of surufatinib-related diarrhea.

Conference:

Presenting Author: Hu S

Authors: Hu S, Guo Y, Chen Y, Cheng Z, Deng C,

Keywords: Surufatinib, diarrhea, model, rat,